ABSTRACT
The molecular and biological characteristics of the vaccine against rabies virus strain ERA-CB 20M obtained by the Russian rabiologist, doctor of medical sciences S.V. Gribencha by adapting and cloning the strain ERA and SAD in a transplantable BHK-21 C13 cell culture are presented. The spectrum of the most sensitive strain of rabies ERA-CB 20M cell lines was determined and the level of glycoprotein was quantitatively determined. Primary nucleotide sequences of fragments of the genome of the strain ERA-CB 20M (genes N and G) were obtained and phylogenetic analysis was carried out. Molecular analysis showed that this strain belongs to the group of vaccine strains SAD1. When compared with the reference strain SAD1, 10% of the nucleotide differences were revealed in the gene fragment N; 15%, in the gene fragment G.
Subject(s)
Rabies Vaccines/genetics , Rabies virus/genetics , Rabies/genetics , Vaccines, Attenuated/therapeutic use , Genome, Viral/genetics , Glycoproteins/genetics , Humans , Rabies/immunology , Rabies/prevention & control , Rabies/virology , Rabies Vaccines/therapeutic use , Rabies virus/pathogenicity , Vaccines, Attenuated/immunologyABSTRACT
The paper describes a new principle of the selection of the rabies virus vaccine strain ERA-CB20M based on quantitation of the expression of glycoprotein, a major immunogen of rabies virus. There is a correlation between the level of glycoprotein expression and that of vaccine virus attenuation. The application of the new principle for vaccine virus selection will permit a safer and more immunogenic rabies vaccine to be prepared.
